Biomedical Science Letters

eISSN 2288-7415

Table. 1.

Comparison among general characteristics of AZ, Janssen, Pfizer, Moderna and Novavax vaccine

Manufacturer Oxford-AstraZeneca vaccine Janssen vaccine Pfizer vaccine Moderna vaccine Novavax vaccine
Trade name Covishield or Vaxzevria Jcovden Comirnaty Spikevax Covovax or Nuvaxovid
Code name AZD1222 (ChAdOx1-S) JNJ-78436735 (Ad26.COV2-S) BNT162 mRNA-1273 NVX-CoV2373
Platform Viral vector Viral vector mRNA mRNA Protein recombinant
Age for vaccination 18 years and older 18 years and older 12 years and older 18 years and older 18 years and older
Composition Multidose vial Multidose vial Multidose vial Multidose vial Prefilled syringe
Number doses/interval dose 2/8~12 weeks 1 2/21 days 2/28 days 2/21 days
Dose volume/site 0.5 mL/IM 0.5 mL/IM dilute 0.3 mL/IM 0.5 mL/IM 0.5 mL/IM
Storage temperature/period 2~8℃/6 months -25 ~ -15℃/24 months -90 ~ -60℃/6 months -25 ~ -15℃/7 months 2~8℃/5 months
Distribution temperature/period 2~8℃/6 months 2~8℃/3 months -90 ~ -60℃/6 months or 2~8℃/31 days 2~8℃/30 days 2~8℃/5 months
Expiry date after opening ~30℃/6 hours 2~8℃/6 hours, 9~25℃/3 hours 2~25℃/6 hours after dilution 2~25℃/6 hours 2~8℃

Data from Korea Disease Control and Prevention Agency

Abbreviation: AZ, Oxford/AstraZeneca; IM, intramuscular injection; modRNA, nucleoside-modified mRNA

Biomed Sci Letters 2022;28:67-82 https://doi.org/10.15616/BSL.2022.28.2.67
© 2022 Biomed Sci Letters